OCGN News & Events

Reports Q1 revenue $1.53M, consensus $358,140. "In the first few months of 2026, we have completed enrollment of two of our late-stage programs and are diligently working toward initiating our first BLA submission for RP and registration trial for dry AMD later this year," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "We are executing well against our plans with the highest productivity per employee rate compared to our peers, adequate cash runway with the recent offering, and key milestone achievement to create long-term value creation for our patients and shareholders."

Ocugen announced its intention to offer, subject to market conditions and other factors, $115M aggregate principal amount of convertible senior notes due 2034 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Ocugen announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST-a modifier gene therapy candidate developed for all Stargardt disease. The OCU410ST Phase 2/3 pivotal confirmatory trial represents Ocugen's second late-stage clinical program. Ocugen plans to submit the BLA for OCU410ST mid-2027 in alignment with its strategic goal of filing three BLAs by 2028.

Biogen (BIIB) has agreed to acquire Apellis Pharmaceuticals (APLS) for $41 per share, bringing complement inhibitors Syfovre and Empaveli into its portfolio, with Syfovre's $589M in 2025 sales viewed as the primary value driver, Chardan tells investors in a research note. The deal underscores strong pharma interest in the complement pathway, particularly in geographic atrophy, and reads positively to peers such as Annexon (ANNX) and Ocugen (OCGN), potentially catalyzing further partnership or licensing activity in the space, the firm says. Chardan has a Buy rating and $16 price target on shares of Annexon.